Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study

Table 1 Comparison of clinicopathological features among the three groups

Variable	Group A (n = 51)	Group B (n = 14)	Group C (n = 16)	χ2 value/F value	P value
Gender (male/female)	44/7	13/1	15/1	0.622	0.784
Age (yr)	54 ± 13 (33-82)	48 ± 11 (25-67)	52 ± 10 (39-67)	1.028	0.461
AFP (μg/L)	353.5 ± 104.5 (143.5-563.4)	121.9 ± 47.5 (19.2-224.6)	326.9 ± 90.6 (133.8-519.9)	0.769	0.467
HBsAg (negative/positive)	4/47	2/12	1/15	0.968	0.728
HBV-DNA (negative/positive)	39/12	7/7	8/8	5.956	0.051
Tumor location (left lobe/right lobe/both lobe )	9/37/5	0/10/4	2/9/5	7.459	0.089
Liver cirrhosis (negative/positive)	23/28	8/6	6/10	1.180	0.554
Tumor cell differentiation (well/moderate/poor)	9/32/10	4/8/2	2/10/4	1.655	0.832
Treatment modality (RFA/RFA + PEI/TACE/LR)	21/20/1/9	4/6/1/3	7/2/4/3	10.933	0.064
Time to recurrence from last treatment (mo)	26.6 ± 3.9 (18.6-34.5)	22.6 ± 4.1 (13.7-31.6)	17.3 ± 5.3 (5.9-28.5)	0.856	0.429
Number of recurrences (first/second)	43/8	10/4	11/5	2.632	0.285

Data are expressed as the mean ± SD. AFP: Alpha-fetal protein; HBsAg: Hepatitis B surface antigen; HBV-DNA: Hepatitis B virus deoxyribonucleic acid; RFA: Radiofrequency ablation; PEI: Percutaneous ethanol injection therapy; TACE: Transarterial chemoembolization; LR: Liver resection.